<DOC>
	<DOCNO>NCT02929615</DOCNO>
	<brief_summary>The purpose study research standard individualize treatment model relapse refractory lymphatic system malignant tumor .</brief_summary>
	<brief_title>Study Standard Individualized Treatment Model Relapse Refractory Lymphatic System Malignant Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Patients relapse refractory lymphoma multiple myeloma . 2 . At least 1 measurable lesion size≥15mm . 3 . Patients ≤65 years，no limitation gender . 4 . ECOG score 01 . 5 . Life expectancy≥3 month . 6 . LVEF≥ 55 % ; Peripheral blood : WBC ≥ 3.5×10 ( 9 ) /L , neutrophil ≥1.5×10 ( 9 ) /L , PLT≥75×109/L，Hb≥90g/L ; Renal function : Cr≤2.0×UNL ; Liver function : BIL≤2.0×UNL，ALT/AST≤2.5×UNL ; 7 . Written inform consent acquire . 1 . Previously receive stem cell transplantation . 2 . Women pregnant , lactate take contraceptive measure . 3 . Severe acute infection suppurative chronic infection wound heal . 4 . Severe heart failure . 5 . Suffering mental disorder poor compliance . 6 . Other situation investigator consider contraindication study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>